Lypsa Gems & Jewellery Limited
Lypsa Gems & Jewellery Limited (LYPSAGEMS.NS) Stock Competitors & Peer Comparison
See (LYPSAGEMS.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Luxury Goods Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LYPSAGEMS.NS | ₹4.65 | +3.56% | 124.4M | -0.89 | -₹4.72 | N/A |
| TITAN.BO | ₹4,063.20 | +2.05% | 3.5T | 84.55 | ₹46.74 | +0.28% |
| TITAN.NS | ₹4,065.50 | +2.11% | 3.5T | 73.51 | ₹53.75 | +0.28% |
| KALYANKJIL.NS | ₹387.10 | -0.32% | 388.2B | 34.33 | ₹10.95 | +0.40% |
| KALYANKJIL.BO | ₹387.10 | -0.32% | 388.1B | 34.32 | ₹10.95 | +0.40% |
| THANGAMAYL.NS | ₹3,552.40 | +3.54% | 106.5B | 44.25 | ₹77.43 | +0.36% |
| THANGAMAYL.BO | ₹3,552.40 | +3.70% | 106.3B | 44.25 | ₹77.28 | +0.36% |
| PNGJL.NS | ₹561.35 | +1.45% | 72.1B | 18.21 | ₹29.15 | N/A |
| BLUESTONE.NS | ₹453.30 | -7.49% | 70.9B | -115.06 | -₹4.06 | N/A |
| ETHOSLTD.NS | ₹2,234.70 | +0.46% | 58.4B | 112.37 | ₹19.43 | N/A |
Stock Comparison
LYPSAGEMS.NS vs TITAN.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, TITAN.BO has a market cap of 3.5T. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while TITAN.BO trades at ₹4,063.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas TITAN.BO's P/E ratio is 84.55. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to TITAN.BO's ROE of +0.42%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TITAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TITAN.BO's competition here
LYPSAGEMS.NS vs TITAN.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, TITAN.NS has a market cap of 3.5T. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while TITAN.NS trades at ₹4,065.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas TITAN.NS's P/E ratio is 73.51. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to TITAN.NS's ROE of +0.42%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TITAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TITAN.NS's competition here
LYPSAGEMS.NS vs KALYANKJIL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, KALYANKJIL.NS has a market cap of 388.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while KALYANKJIL.NS trades at ₹387.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas KALYANKJIL.NS's P/E ratio is 34.33. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to KALYANKJIL.NS's ROE of +0.23%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KALYANKJIL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KALYANKJIL.NS's competition here
LYPSAGEMS.NS vs KALYANKJIL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, KALYANKJIL.BO has a market cap of 388.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while KALYANKJIL.BO trades at ₹387.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas KALYANKJIL.BO's P/E ratio is 34.32. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to KALYANKJIL.BO's ROE of +0.23%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KALYANKJIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KALYANKJIL.BO's competition here
LYPSAGEMS.NS vs THANGAMAYL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, THANGAMAYL.NS has a market cap of 106.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while THANGAMAYL.NS trades at ₹3,552.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas THANGAMAYL.NS's P/E ratio is 44.25. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to THANGAMAYL.NS's ROE of +0.25%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to THANGAMAYL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check THANGAMAYL.NS's competition here
LYPSAGEMS.NS vs THANGAMAYL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, THANGAMAYL.BO has a market cap of 106.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while THANGAMAYL.BO trades at ₹3,552.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas THANGAMAYL.BO's P/E ratio is 44.25. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to THANGAMAYL.BO's ROE of +0.25%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to THANGAMAYL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check THANGAMAYL.BO's competition here
LYPSAGEMS.NS vs PNGJL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, PNGJL.NS has a market cap of 72.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while PNGJL.NS trades at ₹561.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas PNGJL.NS's P/E ratio is 18.21. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to PNGJL.NS's ROE of +0.23%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to PNGJL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check PNGJL.NS's competition here
LYPSAGEMS.NS vs BLUESTONE.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, BLUESTONE.NS has a market cap of 70.9B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while BLUESTONE.NS trades at ₹453.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas BLUESTONE.NS's P/E ratio is -115.06. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to BLUESTONE.NS's ROE of -0.05%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to BLUESTONE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check BLUESTONE.NS's competition here
LYPSAGEMS.NS vs ETHOSLTD.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, ETHOSLTD.NS has a market cap of 58.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while ETHOSLTD.NS trades at ₹2,234.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas ETHOSLTD.NS's P/E ratio is 112.37. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to ETHOSLTD.NS's ROE of +0.09%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to ETHOSLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check ETHOSLTD.NS's competition here
LYPSAGEMS.NS vs ETHOSLTD.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, ETHOSLTD.BO has a market cap of 58.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while ETHOSLTD.BO trades at ₹2,234.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas ETHOSLTD.BO's P/E ratio is 111.54. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to ETHOSLTD.BO's ROE of +0.09%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to ETHOSLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check ETHOSLTD.BO's competition here
LYPSAGEMS.NS vs PCJEWELLER.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, PCJEWELLER.NS has a market cap of 50.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while PCJEWELLER.NS trades at ₹8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas PCJEWELLER.NS's P/E ratio is 10.81. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to PCJEWELLER.NS's ROE of +0.11%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to PCJEWELLER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check PCJEWELLER.NS's competition here
LYPSAGEMS.NS vs PCJEWELLER.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, PCJEWELLER.BO has a market cap of 50.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while PCJEWELLER.BO trades at ₹8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas PCJEWELLER.BO's P/E ratio is 10.74. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to PCJEWELLER.BO's ROE of +0.11%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to PCJEWELLER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check PCJEWELLER.BO's competition here
LYPSAGEMS.NS vs SKYGOLD.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SKYGOLD.NS has a market cap of 49.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SKYGOLD.NS trades at ₹337.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SKYGOLD.NS's P/E ratio is 20.92. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SKYGOLD.NS's ROE of +0.33%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SKYGOLD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SKYGOLD.NS's competition here
LYPSAGEMS.NS vs SKYGOLD.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SKYGOLD.BO has a market cap of 49.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SKYGOLD.BO trades at ₹337.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SKYGOLD.BO's P/E ratio is 20.92. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SKYGOLD.BO's ROE of +0.33%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SKYGOLD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SKYGOLD.BO's competition here
LYPSAGEMS.NS vs SENCO.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SENCO.NS has a market cap of 45.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SENCO.NS trades at ₹288.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SENCO.NS's P/E ratio is 9.50. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SENCO.NS's ROE of +0.26%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SENCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SENCO.NS's competition here
LYPSAGEMS.NS vs SENCO.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SENCO.BO has a market cap of 45.6B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SENCO.BO trades at ₹288.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SENCO.BO's P/E ratio is 9.50. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SENCO.BO's ROE of +0.26%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SENCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SENCO.BO's competition here
LYPSAGEMS.NS vs GOLDIAM.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, GOLDIAM.NS has a market cap of 30.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while GOLDIAM.NS trades at ₹290.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas GOLDIAM.NS's P/E ratio is 19.23. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to GOLDIAM.NS's ROE of +0.20%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to GOLDIAM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check GOLDIAM.NS's competition here
LYPSAGEMS.NS vs GOLDIAM.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, GOLDIAM.BO has a market cap of 30.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while GOLDIAM.BO trades at ₹291.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas GOLDIAM.BO's P/E ratio is 19.19. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to GOLDIAM.BO's ROE of +0.20%. Regarding short-term risk, LYPSAGEMS.NS is less volatile compared to GOLDIAM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check GOLDIAM.BO's competition here
LYPSAGEMS.NS vs VAIBHAVGBL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, VAIBHAVGBL.BO has a market cap of 29.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while VAIBHAVGBL.BO trades at ₹185.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas VAIBHAVGBL.BO's P/E ratio is 14.14. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to VAIBHAVGBL.BO's ROE of +0.15%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to VAIBHAVGBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check VAIBHAVGBL.BO's competition here
LYPSAGEMS.NS vs VAIBHAVGBL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, VAIBHAVGBL.NS has a market cap of 29.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while VAIBHAVGBL.NS trades at ₹185.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas VAIBHAVGBL.NS's P/E ratio is 14.15. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to VAIBHAVGBL.NS's ROE of +0.15%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to VAIBHAVGBL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check VAIBHAVGBL.NS's competition here
LYPSAGEMS.NS vs KDDL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, KDDL.BO has a market cap of 25B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while KDDL.BO trades at ₹2,161.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas KDDL.BO's P/E ratio is 30.03. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to KDDL.BO's ROE of +0.07%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KDDL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KDDL.BO's competition here
LYPSAGEMS.NS vs KDDL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, KDDL.NS has a market cap of 24.9B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while KDDL.NS trades at ₹2,162.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas KDDL.NS's P/E ratio is 29.94. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to KDDL.NS's ROE of +0.07%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KDDL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KDDL.NS's competition here
LYPSAGEMS.NS vs RAJESHEXPO.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RAJESHEXPO.BO has a market cap of 23.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RAJESHEXPO.BO trades at ₹83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RAJESHEXPO.BO's P/E ratio is 14.19. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RAJESHEXPO.BO's ROE of +0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RAJESHEXPO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RAJESHEXPO.BO's competition here
LYPSAGEMS.NS vs RAJESHEXPO.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RAJESHEXPO.NS has a market cap of 23.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RAJESHEXPO.NS trades at ₹83.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RAJESHEXPO.NS's P/E ratio is 14.13. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RAJESHEXPO.NS's ROE of +0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RAJESHEXPO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RAJESHEXPO.NS's competition here
LYPSAGEMS.NS vs DPABHUSHAN.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, DPABHUSHAN.NS has a market cap of 21.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while DPABHUSHAN.NS trades at ₹1,005.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas DPABHUSHAN.NS's P/E ratio is 11.55. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to DPABHUSHAN.NS's ROE of +0.45%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to DPABHUSHAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check DPABHUSHAN.NS's competition here
LYPSAGEMS.NS vs BRIGHOTEL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, BRIGHOTEL.BO has a market cap of 17.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while BRIGHOTEL.BO trades at ₹57.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas BRIGHOTEL.BO's P/E ratio is 43.70. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to BRIGHOTEL.BO's ROE of N/A. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to BRIGHOTEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check BRIGHOTEL.BO's competition here
LYPSAGEMS.NS vs AAYUSHBULL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, AAYUSHBULL.BO has a market cap of 17.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while AAYUSHBULL.BO trades at ₹1,130.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas AAYUSHBULL.BO's P/E ratio is 1004.02. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to AAYUSHBULL.BO's ROE of N/A. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to AAYUSHBULL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check AAYUSHBULL.BO's competition here
LYPSAGEMS.NS vs SHANTIGOLD.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SHANTIGOLD.BO has a market cap of 11.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SHANTIGOLD.BO trades at ₹164.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SHANTIGOLD.BO's P/E ratio is 8.84. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SHANTIGOLD.BO's ROE of +0.37%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SHANTIGOLD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SHANTIGOLD.BO's competition here
LYPSAGEMS.NS vs SHANTIGOLD.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SHANTIGOLD.NS has a market cap of 11.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SHANTIGOLD.NS trades at ₹164.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SHANTIGOLD.NS's P/E ratio is 8.77. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SHANTIGOLD.NS's ROE of +0.37%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SHANTIGOLD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SHANTIGOLD.NS's competition here
LYPSAGEMS.NS vs MOTISONS.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, MOTISONS.NS has a market cap of 10.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while MOTISONS.NS trades at ₹12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas MOTISONS.NS's P/E ratio is -57.00. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to MOTISONS.NS's ROE of +0.16%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MOTISONS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MOTISONS.NS's competition here
LYPSAGEMS.NS vs RGL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RGL.NS has a market cap of 10.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RGL.NS trades at ₹101.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RGL.NS's P/E ratio is 10.97. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RGL.NS's ROE of +0.06%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RGL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RGL.NS's competition here
LYPSAGEMS.NS vs RGL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RGL.BO has a market cap of 10.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RGL.BO trades at ₹101.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RGL.BO's P/E ratio is 10.92. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RGL.BO's ROE of +0.06%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RGL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RGL.BO's competition here
LYPSAGEMS.NS vs TBZ.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, TBZ.NS has a market cap of 7.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while TBZ.NS trades at ₹126.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas TBZ.NS's P/E ratio is 5.16. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to TBZ.NS's ROE of +0.22%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TBZ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TBZ.NS's competition here
LYPSAGEMS.NS vs TBZ.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, TBZ.BO has a market cap of 7.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while TBZ.BO trades at ₹126.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas TBZ.BO's P/E ratio is 5.16. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to TBZ.BO's ROE of +0.22%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TBZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TBZ.BO's competition here
LYPSAGEMS.NS vs MVGJL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, MVGJL.BO has a market cap of 6.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while MVGJL.BO trades at ₹144.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas MVGJL.BO's P/E ratio is 5.71. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to MVGJL.BO's ROE of +0.16%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MVGJL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MVGJL.BO's competition here
LYPSAGEMS.NS vs MVGJL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, MVGJL.NS has a market cap of 6.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while MVGJL.NS trades at ₹143.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas MVGJL.NS's P/E ratio is 5.68. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to MVGJL.NS's ROE of +0.16%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MVGJL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MVGJL.NS's competition here
LYPSAGEMS.NS vs RADHIKAJWE.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RADHIKAJWE.BO has a market cap of 6B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RADHIKAJWE.BO trades at ₹56.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RADHIKAJWE.BO's P/E ratio is 7.39. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RADHIKAJWE.BO's ROE of +0.24%. Regarding short-term risk, LYPSAGEMS.NS is less volatile compared to RADHIKAJWE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RADHIKAJWE.BO's competition here
LYPSAGEMS.NS vs RADHIKAJWE.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RADHIKAJWE.NS has a market cap of 6B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RADHIKAJWE.NS trades at ₹56.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RADHIKAJWE.NS's P/E ratio is 7.37. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RADHIKAJWE.NS's ROE of +0.24%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RADHIKAJWE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RADHIKAJWE.NS's competition here
LYPSAGEMS.NS vs LGHL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, LGHL.NS has a market cap of 4.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while LGHL.NS trades at ₹233.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas LGHL.NS's P/E ratio is 100.93. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to LGHL.NS's ROE of +0.15%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to LGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check LGHL.NS's competition here
LYPSAGEMS.NS vs RBZJEWEL.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RBZJEWEL.NS has a market cap of 4.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RBZJEWEL.NS trades at ₹116.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RBZJEWEL.NS's P/E ratio is 7.90. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RBZJEWEL.NS's ROE of +0.21%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RBZJEWEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RBZJEWEL.NS's competition here
LYPSAGEMS.NS vs SILGO.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, SILGO.NS has a market cap of 1.9B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while SILGO.NS trades at ₹74.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas SILGO.NS's P/E ratio is 28.65. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to SILGO.NS's ROE of +0.08%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SILGO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SILGO.NS's competition here
LYPSAGEMS.NS vs MOKSH.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, MOKSH.NS has a market cap of 722.8M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while MOKSH.NS trades at ₹9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas MOKSH.NS's P/E ratio is 6.90. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to MOKSH.NS's ROE of +0.09%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MOKSH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MOKSH.NS's competition here
LYPSAGEMS.NS vs EFORU.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, EFORU.BO has a market cap of 526.2M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while EFORU.BO trades at ₹88.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas EFORU.BO's P/E ratio is 48.09. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to EFORU.BO's ROE of +0.47%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to EFORU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check EFORU.BO's competition here
LYPSAGEMS.NS vs RRETAIL.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, RRETAIL.BO has a market cap of 404.4M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while RRETAIL.BO trades at ₹2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas RRETAIL.BO's P/E ratio is -25.80. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to RRETAIL.BO's ROE of -0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RRETAIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RRETAIL.BO's competition here
LYPSAGEMS.NS vs GOENKA.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, GOENKA.NS has a market cap of 259.9M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while GOENKA.NS trades at ₹0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas GOENKA.NS's P/E ratio is -27.33. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to GOENKA.NS's ROE of -0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to GOENKA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check GOENKA.NS's competition here
LYPSAGEMS.NS vs KANANIIND.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, KANANIIND.BO has a market cap of 211.7M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while KANANIIND.BO trades at ₹1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas KANANIIND.BO's P/E ratio is 11.89. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to KANANIIND.BO's ROE of +0.03%. Regarding short-term risk, LYPSAGEMS.NS is less volatile compared to KANANIIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KANANIIND.BO's competition here
LYPSAGEMS.NS vs KANANIIND.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, KANANIIND.NS has a market cap of 209.7M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while KANANIIND.NS trades at ₹1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas KANANIIND.NS's P/E ratio is 11.78. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to KANANIIND.NS's ROE of +0.03%. Regarding short-term risk, LYPSAGEMS.NS is less volatile compared to KANANIIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KANANIIND.NS's competition here
LYPSAGEMS.NS vs ZODJRDMKJ.NS Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, ZODJRDMKJ.NS has a market cap of 164.9M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while ZODJRDMKJ.NS trades at ₹31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas ZODJRDMKJ.NS's P/E ratio is 24.13. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to ZODJRDMKJ.NS's ROE of +0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to ZODJRDMKJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check ZODJRDMKJ.NS's competition here
LYPSAGEMS.NS vs LYPSAGEMS.BO Comparison April 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 124.4M. In comparison, LYPSAGEMS.BO has a market cap of 124.4M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.65, while LYPSAGEMS.BO trades at ₹4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -0.89, whereas LYPSAGEMS.BO's P/E ratio is -0.89. In terms of profitability, LYPSAGEMS.NS's ROE is -0.68%, compared to LYPSAGEMS.BO's ROE of -0.68%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to LYPSAGEMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check LYPSAGEMS.BO's competition here